Manufacturing Possibility ?
Biogen plans $1 billion plant in Switzerland (Article in Boston Globe July 2015)
By Robert Weisman GLOBE STAFF JULY 01, 2015
The Cambridge biotechnology giant Biogen Inc. plans to invest $1 billion in a new manufacturing plant in northern Switzerland that would triple the company’s global capacity to produce large protein-based drugs known as biologics.
Excerpt from Biogen's website
Manufacturing capabilities
Our quality team manages compliance and supervises consistent and dependable production of our therapies, while our supply chain group makes sure that we are able to get our therapies to patients, when and where they need them. The combination of these skills and focuses enable us to manufacture and supply medicines to patients in more than 90 countries.
In the coming years we expect to substantially increase our production capabilities by focusing on innovation that allows us to scale in advance of new pipeline products. Today we can rapidly increase production of small molecules and biologics, providing flexibility and protection to our supply chain.
In addition BIIB might have excess capacity due to the recent reduction of some of their pursuits.
News 
Market Data 
Discover 
